Prime Medicine Inc (NASDAQ: PRME) on Friday, soared 10.25% from the previous trading day, before settling in for the closing price of $3.22. Within the past 52 weeks, PRME’s price has moved between $1.11 and $5.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -124.13%. The company achieved an average annual earnings per share of 28.42%. With a float of $94.42 million, this company’s outstanding shares have now reached $134.49 million.
Prime Medicine Inc (PRME) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Prime Medicine Inc is 47.02%, while institutional ownership is 22.11%. The most recent insider transaction that took place on Aug 01 ’25, was worth 4,950,000. In this transaction 10% Owner of this company bought 1,500,000 shares at a rate of $3.30, taking the stock ownership to the 3,262,440 shares. Before that another transaction happened on Aug 01 ’25, when Company’s Director bought 3,030,300 for $3.30, making the entire transaction worth $9,999,990. This insider now owns 6,230,300 shares in total.
Prime Medicine Inc (PRME) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.44 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.42) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.11% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Prime Medicine Inc (PRME) is currently performing well based on its current performance indicators. A quick ratio of 3.56 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 127.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.60, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.89 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Looking closely at Prime Medicine Inc (NASDAQ: PRME), its last 5-days average volume was 3.15 million, which is a jump from its year-to-date volume of 2.53 million. As of the previous 9 days, the stock’s Stochastic %D was 31.69%.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 60.10%, which indicates a significant increase from 32.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.31 in the past 14 days, which was higher than the 0.28 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.46, while its 200-day Moving Average is $2.64. However, in the short run, Prime Medicine Inc’s stock first resistance to watch stands at $3.71. Second resistance stands at $3.88. The third major resistance level sits at $4.11. If the price goes on to break the first support level at $3.31, it is likely to go to the next support level at $3.08. Should the price break the second support level, the third support level stands at $2.91.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
Market capitalization of the company is 632.61 million based on 134,574K outstanding shares. Right now, sales total 2,980 K and income totals -195,880 K. The company made 1,120 K in profit during its latest quarter, and -52,590 K in sales during its previous quarter.
